SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Michael Gnant, Role of bisphosphonates in postmenopausal women with breast cancer, Cancer Treatment Reviews, 2014, 40, 3, 476

    CrossRef

  2. 2
    Pooleriveetil Padikkal Anagha, Suchandra Sen, The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis, Journal of Oncology, 2014, 2014, 1

    CrossRef

  3. 3
    Xiao-Long Xu, Wen-Long Gou, Ai-Yuan Wang, Yu Wang, Quan-Yi Guo, Qiang Lu, Shi-Bi Lu, Jiang Peng, Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?, Journal of Translational Medicine, 2013, 11, 1, 303

    CrossRef

  4. 4
    M.C. Winter, R.E. Coleman, Bisphosphonates in the Adjuvant Treatment of Breast Cancer, Clinical Oncology, 2013, 25, 2, 135

    CrossRef

  5. 5
    Alexander Paterson, Melissa Shea-Budgell, Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline, Journal of Clinical Medicine, 2013, 2, 4, 283

    CrossRef

  6. 6
    Peyman Hadji, Matthias Frank, Andreas Jakob, Jan Willem Siebers, Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort, Journal of Bone Oncology, 2013, 2, 1, 2

    CrossRef

  7. 7
    M. Poon, L. Zeng, L. Zhang, H. Lam, U. Emmenegger, E. Wong, G. Bedard, N. Lao, R. Chow, E. Chow, Incidence of Skeletal-related Events Over Time from Solid Tumour Bone Metastases Reported in Randomised Trials Using Bone-modifying Agents, Clinical Oncology, 2013, 25, 7, 435

    CrossRef

  8. 8
    M. Capelan, L. Pugliano, E. De Azambuja, I. Bozovic, K. S. Saini, C. Sotiriou, S. Loi, M. J. Piccart-Gebhart, Pertuzumab: new hope for patients with HER2-positive breast cancer, Annals of Oncology, 2013, 24, 2, 273

    CrossRef

  9. 9
    Hiroji Uemura, Masahiro Yanagisawa, Ichirou Ikeda, Kiyoshi Fujinami, Akira Iwasaki, Sumio Noguchi, Kazumi Noguchi, Yoshinobu Kubota, Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial, International Journal of Clinical Oncology, 2013, 18, 3, 472

    CrossRef

  10. 10
    Neeraj Kumar Agrawal, Ved Prakash, Kiran Singh, Saving the bones in breast cancer: aromatase inhibitor-induced osteoporosis, Expert Review of Endocrinology & Metabolism, 2013, 8, 4, 311

    CrossRef

  11. 11
    Susan M. DeLange Hudec, Pauline M. Camacho, Secondary Causes of Osteoporosis, Endocrine Practice, 2013, 19, 1, 120

    CrossRef

  12. 12
    Yu Zheng, Hong Zhou, Colin R. Dunstan, Robert L. Sutherland, Markus J. Seibel, The role of the bone microenvironment in skeletal metastasis, Journal of Bone Oncology, 2013, 2, 1, 47

    CrossRef

  13. 13
    R. Coleman, R. de Boer, H. Eidtmann, A. Llombart, N. Davidson, P. Neven, G. von Minckwitz, H. P. Sleeboom, J. Forbes, C. Barrios, A. Frassoldati, I. Campbell, O. Paija, N. Martin, A. Modi, N. Bundred, Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results, Annals of Oncology, 2013, 24, 2, 398

    CrossRef

  14. 14
    Christos Markopoulos, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, Basileios Venizelos, Vasilios Zobolas, John Misitzis, Grigorios Xepapadakis, Helen Gogas, Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial, Journal of Cancer Research and Clinical Oncology, 2012, 138, 9, 1569

    CrossRef

  15. 15
    Nigel Bundred, Antiresorptive therapies in oncology and their effects on cancer progression, Cancer Treatment Reviews, 2012, 38, 6, 776

    CrossRef

  16. 16
    Mary Ellen Pavone, Serdar E. Bulun, Aromatase inhibitors for the treatment of endometriosis, Fertility and Sterility, 2012, 98, 6, 1370

    CrossRef

  17. 17
    Jean-Jacques Body, Aromatase inhibitors-induced bone loss in early breast cancer, BoneKEy Reports, 2012, 1, 201

    CrossRef

  18. 18
    F. Nuzzo, C. Gallo, S. Lastoria, M. Di Maio, M. C. Piccirillo, A. Gravina, G. Landi, E. Rossi, C. Pacilio, V. Labonia, F. Di Rella, A. Bartiromo, G. Buonfanti, G. De Feo, G. Esposito, R. D'Aniello, P. Maiolino, S. Signoriello, E. De Maio, V. Tinessa, G. Colantuoni, M. De Laurentiis, M. D'Aiuto, M. Di Bonito, G. Botti, P. Giordano, G. Daniele, A. Morabito, N. Normanno, A. de Matteis, F. Perrone, Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study, Annals of Oncology, 2012, 23, 8, 2027

    CrossRef

  19. 19
    Rakhshanda Layeequr Rahman, Sandhya Pruthi, Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction, Cancers, 2012, 4, 4, 1146

    CrossRef

  20. 20
    Shunji Takahashi, Takuji Iwase, Norio Kohno, Takashi Ishikawa, Tetsuya Taguchi, Masato Takahashi, Jun Horiguchi, Seigo Nakamura, Yasuo Hozumi, Masao Fukunaga, Shinzaburo Noguchi, Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results, Breast Cancer Research and Treatment, 2012, 133, 2, 685

    CrossRef

  21. 21
    Adam M. Brufsky, W. Graydon Harker, J. Thaddeus Beck, Linda Bosserman, Charles Vogel, Christopher Seidler, Lixian Jin, Ghulam Warsi, Eliza Argonza-Aviles, John Hohneker, Solveig G. Ericson, Edith A. Perez, Final 5-year results of Z-FAST trial, Cancer, 2012, 118, 5
  22. 22
    R. Rizzoli, J. J. Body, A. Censi, J. Y. Reginster, P. Piscitelli, M. L. Brandi, Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper, Osteoporosis International, 2012, 23, 11, 2567

    CrossRef

  23. 23
    Antonio Llombart, Antonio Frassoldati, Outi Paija, Harm Peter Sleeboom, Guy Jerusalem, Jeroen Mebis, Ines Deleu, Joel Miller, Nora Schenk, Patrick Neven, Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial, Clinical Breast Cancer, 2012, 12, 1, 40

    CrossRef

  24. 24
    Jennifer A. Ligibel, A. James O’Malley, Maxine Fisher, Gregory W. Daniel, Eric P. Winer, Nancy L. Keating, Patterns of bone density evaluation in a community population treated with aromatase inhibitors, Breast Cancer Research and Treatment, 2012, 134, 3, 1305

    CrossRef

  25. 25
    Catalina Orozco, Naim M. Maalouf, Safety of Bisphosphonates, Rheumatic Disease Clinics of North America, 2012, 38, 4, 681

    CrossRef

  26. 26
    Michael Poon, Liang Zeng, Liying Zhang, Marko Popovic, Ronald Chow, Henry Lam, Gillian Bedard, Urban Emmenegger, Christine Simmons, Edward Chow, Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials, Journal of Bone Oncology, 2012, 1, 3, 74

    CrossRef

  27. 27
    Tingting Yan, Wenjin Yin, Qiong Zhou, Liheng Zhou, Yiwei Jiang, Yueyao Du, Zhimin Shao, Jinsong Lu, The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials, European Journal of Cancer, 2012, 48, 2, 187

    CrossRef

  28. 28
    P. Hadji, R. Coleman, M. Gnant, J. Green, The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis, Annals of Oncology, 2012, 23, 11, 2782

    CrossRef

  29. 29
    Nigel J Bundred, Peter Kenemans, Cheng Yip, Matthias W Beckmann, Jean-Michel Foidart, Piero Sismondi, Bo Schoultz, Rena Vassilopoulou-Sellin, Rachid Galta, Eugenie Lieshout, Mirjam Mol-Arts, Juan Planellas, Ernst Kubista, Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy, Breast Cancer Research, 2012, 14, 1, R13

    CrossRef

  30. 30
    Daniel Prieto-Alhambra, Sonia Servitja, M. Kassim Javaid, Laia Garrigós, Nigel K. Arden, Cyrus Cooper, Joan Albanell, Ignasi Tusquets, Adolfo Diez-Perez, Xavier Nogues, Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study, Breast Cancer Research and Treatment, 2012, 133, 3, 1159

    CrossRef

  31. 31
    Jonathan Gregory, Paul Cool, Mercer's Textbook of Orthopaedics and Trauma Tenth edition, 2012,

    CrossRef

  32. You have free access to this content32
    Ari VanderWalde, Arti Hurria, Aging and osteoporosis in breast and prostate cancer, CA: A Cancer Journal for Clinicians, 2011, 61, 3
  33. 33
    Gennaro Daniele, Pasqualina Giordano, Antonella De Luca, Maria Carmela Piccirillo, Massimo Di Maio, Antonia Del Giudice, Gianfranco De Feo, Jane Bryce, Luana Lamura, Aldo Vecchione, Nicola Normanno, Francesco Perrone, Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence, Expert Review of Anticancer Therapy, 2011, 11, 2, 299

    CrossRef

  34. 34
    Stéphanie Gaillard, Vered Stearns, Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management, Breast Cancer Research, 2011, 13, 2, 205

    CrossRef

  35. 35
    Jane Bryce, Martina Bauer, Peyman Hadji, Aromatase Inhibitor-Associated Bone Loss, Oncology Nursing Forum, 2011, 38, 3, 273

    CrossRef

  36. 36
    Osama Hussein, Svetlana V. Komarova, Breast cancer at bone metastatic sites: recent discoveries and treatment targets, Journal of Cell Communication and Signaling, 2011, 5, 2, 85

    CrossRef

  37. 37
    Peyman Hadji, Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease, Critical Reviews in Oncology/Hematology, 2011, 80, 2, 301

    CrossRef

  38. 38
    Peyman Hadji, Michael Gnant, Matti Aapro, Allan Lipton, Robert Coleman, Dosing of zoledronic acid throughout the treatment continuum in breast cancer, Critical Reviews in Oncology/Hematology, 2011, 79, 2, 175

    CrossRef

  39. 39
    Seung Ah Lee, Seung Hyun Hwang, Sung Gwe Ahn, Hak Min Lee, Joon Jeong, Hy-De Lee, Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients, Breast Cancer Research and Treatment, 2011, 130, 3, 863

    CrossRef

  40. 40
    R. Eastell, J. Adams, G. Clack, A. Howell, J. Cuzick, J. Mackey, M. W. Beckmann, R. E. Coleman, Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial, Annals of Oncology, 2011, 22, 4, 857

    CrossRef

  41. 41
    Faryal Sardar Ali Mirza, Management of Bone Disease in Patients Undergoing Hormonal Therapy for Breast Cancer, Endocrinology and Metabolism Clinics of North America, 2011, 40, 3, 549

    CrossRef

  42. 42
    S. Loibl, A. Lintermans, A.S. Dieudonné, P. Neven, Management of menopausal symptoms in breast cancer patients, Maturitas, 2011, 68, 2, 148

    CrossRef

  43. 43
    Antonella De Luca, Luana Lamura, Marianna Gallo, Gennaro Daniele, Amelia D'Alessio, Pasqualina Giordano, Monica Rosaria Maiello, Maria Pergameno, Francesco Perrone, Nicola Normanno, Pharmacokinetic evaluation of zoledronic acid, Expert Opinion on Drug Metabolism & Toxicology, 2011, 7, 7, 911

    CrossRef

  44. 44
    Jack Cuzick, Andrea DeCensi, Banu Arun, Powel H Brown, Monica Castiglione, Barbara Dunn, John F Forbes, Agnes Glaus, Anthony Howell, Gunter von Minckwitz, Victor Vogel, Heinz Zwierzina, Preventive therapy for breast cancer: a consensus statement, The Lancet Oncology, 2011, 12, 5, 496

    CrossRef

  45. 45
    S. Aebi, T. Davidson, G. Gruber, F. Cardoso, Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, 2011, 22, Supplement 6, vi12

    CrossRef

  46. 46
    E. Michael Lewiecki, Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis, Drugs, 2011, 71, 6, 791

    CrossRef

  47. 47
    Robert Coleman, The use of bisphosphonates in cancer treatment, Annals of the New York Academy of Sciences, 2011, 1218, 1
  48. 48
    Daniel Prieto-Alhambra, M. Kassim Javaid, Sonia Servitja, Nigel K. Arden, Maria Martinez-García, Adolfo Diez-Perez, Joan Albanell, Ignasi Tusquets, Xavier Nogues, Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study, Breast Cancer Research and Treatment, 2011, 125, 3, 869

    CrossRef

  49. 49
    Sigrun Ressler, Brigitte Mlineritsch, Richard Greil, Zoledronic acid for adjuvant use in patients with breast cancer, Expert Review of Anticancer Therapy, 2011, 11, 3, 333

    CrossRef

  50. 50
    Robert Coleman, Richard Cook, Vera Hirsh, Pierre Major, Allan Lipton, Zoledronic acid use in cancer patients, Cancer, 2011, 117, 1
  51. 51
    Fiona M. McCaig, Lorna Renshaw, Linda Williams, Oliver Young, Juliette Murray, Elizabeth J. Macaskill, Mary McHugh, Rosemary Hannon, J. Michael Dixon, A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer, Breast Cancer Research and Treatment, 2010, 119, 3, 643

    CrossRef

  52. 52
    Kevin R. Fox, Adding Zoledronic Acid to Endocrine Therapy in the Adjuvant Treatment of Hormone-Sensitive Breast Cancer in Premenopausal Women: A New Care Standard or a Provocative Idea?, Current Oncology Reports, 2010, 12, 1, 1

    CrossRef

  53. 53
    L. C. Hofbauer, C. Hamann, P. R. Ebeling, Approach to the patient with secondary osteoporosis, European Journal of Endocrinology, 2010, 162, 6, 1009

    CrossRef

  54. 54
    Xinmin Zhao, Xiaofeng Xu, Lin Guo, Joseph Ragaz, Haiyi Guo, Jiong Wu, Zhimin Shao, Ji Zhu, Xiaomao Guo, Jiayi Chen, Beiling Zhu, Zhonghua Wang, Xichun Hu, Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance, Breast Cancer Research and Treatment, 2010, 124, 3, 733

    CrossRef

  55. 55
    Richard L Theriault, Bisphosphonates: ready for use as adjuvant therapy of breast cancer?, Current Opinion in Obstetrics and Gynecology, 2010, 22, 1, 61

    CrossRef

  56. 56
    Pavani Chalasani, Leona Downey, Alison T. Stopeck, Caring for the Breast Cancer Survivor: A Guide for Primary Care Physicians, The American Journal of Medicine, 2010, 123, 6, 489

    CrossRef

  57. 57
    Matti S. Aapro, Challenges in Clinical Patient Management, Cancer Investigation, 2010, 28, Supplement 1, 14

    CrossRef

  58. 58
    Thomas E. Delea, Charu Taneja, Oleg Sofrygin, Satyin Kaura, Michael Gnant, Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women With Hormone-Responsive Early Breast Cancer, Clinical Breast Cancer, 2010, 10, 4, 267

    CrossRef

  59. 59
    J. F. S. Logman, B. M. S. Heeg, M. F. Botteman, S. Kaura, B. A. van Hout, Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK, Annals of Oncology, 2010, 21, 7, 1529

    CrossRef

  60. 60
    Rebecca Aft, Michael Naughton, Kathryn Trinkaus, Mark Watson, Lourdes Ylagan, Mariana Chavez-MacGregor, Jing Zhai, Sacha Kuo, William Shannon, Kathryn Diemer, Virginia Herrmann, Jill Dietz, Amjad Ali, Matthew Ellis, Peter Weiss, Timothy Eberlein, Cynthia Ma, Paula M Fracasso, Imran Zoberi, Marie Taylor, William Gillanders, Timothy Pluard, Joanne Mortimer, Katherine Weilbaecher, Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial, The Lancet Oncology, 2010, 11, 5, 421

    CrossRef

  61. 61
    H. Eidtmann, R. de Boer, N. Bundred, A. Llombart-Cussac, N. Davidson, P. Neven, G. von Minckwitz, J. Miller, N. Schenk, R. Coleman, Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study, Annals of Oncology, 2010, 21, 11, 2188

    CrossRef

  62. 62
    Jürgen Geisler, Per E. Lønning, Impact of aromatase inhibitors on bone health in breast cancer patients, The Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 4-5, 294

    CrossRef

  63. 63
    Peyman Hadji, Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy, Critical Reviews in Oncology/Hematology, 2010, 73, 2, 156

    CrossRef

  64. 64
    Zeina Nahleh, Judith Abrams, Ashish Bhargaval, Kavita Nirmal, John J. Graff, Outcome of Patients With Early Breast Cancer Receiving Nitrogen-Containing Bisphosphonates: A Comparative Analysis From the Metropolitan Detroit Cancer Surveillance System, Clinical Breast Cancer, 2010, 10, 6, 459

    CrossRef

  65. 65
    S. Aebi, T. Davidson, G. Gruber, M. Castiglione, Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, 2010, 21, Supplement 5, v9

    CrossRef

  66. 66
    Ticiana Leal, Amyé Tevaarwerk, Richard Love, James Stewart, Neil Binkley, Jens Eickhoff, Benjamin Parrot, Daniel Mulkerin, Randomized Trial of Adjuvant Zoledronic Acid in Postmenopausal Women With High-Risk Breast Cancer, Clinical Breast Cancer, 2010, 10, 6, 471

    CrossRef

  67. 67
    M.N.G. Dukes, Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions, 2010,

    CrossRef

  68. 68
    E. Michael Lewiecki, Sanford Baim, John P. Bilezikian, Richard Eastell, Meryl S. LeBoff, Paul D. Miller, 2008 Santa Fe Bone Symposium: Update on Osteoporosis, Journal of Clinical Densitometry, 2009, 12, 2, 135

    CrossRef

  69. 69
    Hamid Mirshahidi, Adding zoledronic acid: a further step to the cure in breast cancer patients, Community Oncology, 2009, 6, 1, 12

    CrossRef

  70. 70
    Orit C. Freedman, Eitan Amir, Mark J. Clemons, Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?, Critical Reviews in Oncology/Hematology, 2009, 72, 1, 56

    CrossRef

  71. 71
    Filippo De Marinis, Wilfried Eberhardt, Peter G. Harper, Bartomeu Massuti Sureda, Kristiaan Nackaerts, Jens Benn Soerensen, Kostas Syrigos, Jean Trédaniel, Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases, Journal of Thoracic Oncology, 2009, 4, 10, 1280

    CrossRef

  72. 72
    Jason M Hollander, Jeffrey I Mechanick, Bisphosphonates and metabolic bone disease in the ICU, Current Opinion in Clinical Nutrition and Metabolic Care, 2009, 12, 2, 190

    CrossRef

  73. 73
    Matthew C Winter, Robert E Coleman, Bisphosphonates in breast cancer: teaching an old dog new tricks, Current Opinion in Oncology, 2009, 21, 6, 499

    CrossRef

  74. 74
    Bhoomi Mehrotra, Bisphosphonates—Role in Cancer Therapies, Journal of Oral and Maxillofacial Surgery, 2009, 67, 5, 19

    CrossRef

  75. 75
    Sheila A Doggrell, Clinical efficacy and safety of zoledronic acid in prostate and breast cancer, Expert Review of Anticancer Therapy, 2009, 9, 9, 1211

    CrossRef

  76. 76
    Georgiana K. Ellis, Henry G. Bone, Rowan Chlebowski, Devchand Paul, Silvana Spadafora, Michelle Fan, Dennis Kim, Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study, Breast Cancer Research and Treatment, 2009, 118, 1, 81

    CrossRef

  77. 77
    Michael Gnant, Brigitte Mlineritsch, Walter Schippinger, Gero Luschin-Ebengreuth, Sabine Pöstlberger, Christian Menzel, Raimund Jakesz, Michael Seifert, Michael Hubalek, Vesna Bjelic-Radisic, Hellmut Samonigg, Christoph Tausch, Holger Eidtmann, Günther Steger, Werner Kwasny, Peter Dubsky, Michael Fridrik, Florian Fitzal, Michael Stierer, Ernst Rücklinger, Richard Greil, Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer, New England Journal of Medicine, 2009, 360, 7, 679

    CrossRef

  78. 78
    Gillian M. Keating, Letrozole, Drugs, 2009, 69, 12, 1681

    CrossRef

  79. 79
    Myra Barginear, Anne Clotfelter, Catherine Van Poznak, Markers of Bone Metabolism in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer, Clinical Breast Cancer, 2009, 9, 2, 72

    CrossRef

  80. 80
    Robert Coleman, Michael Gnant, New results from the use of bisphosphonates in cancer patients, Current Opinion in Supportive and Palliative Care, 2009, 3, 3, 213

    CrossRef

  81. 81
    David M. Reid, Prevention of osteoporosis after breast cancer, Maturitas, 2009, 64, 1, 4

    CrossRef

  82. 82
    F. Trémollieres, J.-M. Pouilles, C. Ribot, Proposition d’une stratégie de prévention du risque fracturaire en début de ménopause, Gynécologie Obstétrique & Fertilité, 2009, 37, 1, 50

    CrossRef

  83. 83
    Masakazu Toi, Hiroyasu Yamashiro, Wakako Tsuji, Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer, Breast Cancer, 2009, 16, 3, 207

    CrossRef

  84. 84
    &NA;, Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women, Drugs & Therapy Perspectives, 2009, 25, 10, 23

    CrossRef

  85. 85
    Adam M. Brufsky, Linda D. Bosserman, Richard R. Caradonna, Barbara B. Haley, C. Michael Jones, Halle C.F. Moore, Lixian Jin, Ghulam M. Warsi, Solveig G. Ericson, Edith A. Perez, Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results, Clinical Breast Cancer, 2009, 9, 2, 77

    CrossRef

  86. 86
    Sundus Ozair, Shabana Iqbal, Efficacy and safety of aromatase inhibitors in early breast cancer, Expert Opinion on Drug Safety, 2008, 7, 5, 547

    CrossRef

  87. 87
    David M. Reid, Julie Doughty, Richard Eastell, Steven D. Heys, Anthony Howell, Eugene V. McCloskey, Trevor Powles, Peter Selby, Robert E. Coleman, Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group, Cancer Treatment Reviews, 2008, 34, S3

    CrossRef

  88. 88
    Katherine A Lyseng-Williamson, Zoledronic Acid, Drugs, 2008, 68, 18, 2661

    CrossRef

  89. 89
    Adam M Brufsky, Zoledronic acid for cancer therapy-induced and postmenopausal bone loss, Expert Opinion on Pharmacotherapy, 2008, 9, 6, 1013

    CrossRef

  90. 90
    Daphne Tsoi, Aliya Khan, Anna K Nowak, Sunil Verma, Thomas Ferguson, Kathleen Pritchard, Angela M Cheung, Bisphosphonates for prevention of bone loss in women with early breast cancer, The Cochrane Library,